Compare GYRE & DNUT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GYRE | DNUT |
|---|---|---|
| Founded | 2002 | 1937 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Food Chains |
| Sector | Health Care | Consumer Staples |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 606.4M | 598.2M |
| IPO Year | 2004 | 2021 |
| Metric | GYRE | DNUT |
|---|---|---|
| Price | $6.68 | $3.39 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 2 | 5 |
| Target Price | ★ $17.00 | $4.15 |
| AVG Volume (30 Days) | 45.0K | ★ 2.9M |
| Earning Date | 05-08-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $275,000.00 | ★ $1,522,616,000.00 |
| Revenue This Year | $19.88 | $0.55 |
| Revenue Next Year | N/A | $3.59 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $5.44 | $2.88 |
| 52 Week High | $9.42 | $5.11 |
| Indicator | GYRE | DNUT |
|---|---|---|
| Relative Strength Index (RSI) | 58.90 | 54.88 |
| Support Level | $5.67 | $3.26 |
| Resistance Level | $8.28 | $3.52 |
| Average True Range (ATR) | 0.32 | 0.16 |
| MACD | 0.08 | 0.03 |
| Stochastic Oscillator | 78.83 | 70.82 |
Gyre Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of small-molecule therapies for the treatment of organ fibrosis and inflammatory diseases. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.
Krispy Kreme Inc is a sweet-treat brand company. The company's Original Glazed doughnut is recognized for its hot-off-the-line, melt-in-mouth experience. It operates through its network of fresh Doughnut Shops, partnerships with retailers, and a growing e-commerce and delivery business. The company conducts its business through the following three reported segments: U.S., which includes all operations in the United States; International, which includes operations in the U.K., Ireland, Australia, New Zealand, Canada, Japan, and Mexico; and Market Development, which includes franchise operations world-wide. It derives maximum revenue from the U.S. segment.